`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`
`
`
`
`INNOPHARMA LICENSING, INC., INNOPHARMA LICENSING LLC,
`INNOPHARMA INC., INNOPHARMA LLC,
`MYLAN PHARMACEUTICALS INC., MYLAN INC., LUPIN LTD. and LUPIN
`PHARMACEUTICALS INC.
`Petitioner,
`
`v.
`
`SENJU PHARMACEUTICAL CO., LTD., BAUSCH & LOMB, INC., and
`BAUSCH & LOMB PHARMA HOLDINGS CORP.
`Patent Owner.
`
`
`
`Case IPR2015-00902 (Patent 8,669,290 B2)
` Case IPR2015-00903 (Patent 8,129,431 B2)1
`
`
`
`Filed: March 18, 2016
`
`PETITIONER’S MOTION TO SEAL
`
`
`1 A word-for-word identical paper has been filed in each proceeding identified in
`
`the heading. IPR2015-01871 has been joined with IPR2015-00903 and includes
`
`Petitioners Lupin Ltd. and Lupin Pharmaceuticals Inc. in addition to the parties
`
`identified above.
`
`
`
`
`
`
`
`Pursuant to 37 C.F.R. §§ 42.14 and 42.55 and the Protective Order (Paper
`
`36) entered in this proceeding, Petitioner hereby moves to seal the following
`
`categories of exhibits:
`
`(1) deposition transcripts designated by Patent Owner as containing
`
`confidential information under the Proposed Stipulated Protective Order
`
`(Paper 36 in IPR2015-00902; Paper 38 in IPR2015-00903) (“Proposed
`
`Stipulated Protective Order”);
`
`(2) documents from a concurrent district court proceeding before the
`
`United States District Court for the District of New Jersey in Senju
`
`Pharmaceutical Co., Ltd. et al. v. InnoPharma Licensing, Inc. et al., C.A.
`
`No. 1:14-cv-06893-JBS-KMW
`
`(D.N.J.
`
`filed Nov. 3, 2014) and
`
`corresponding cases designated by Patent Owner as Confidential pursuant to
`
`the Discovery Confidentiality Order (ECF No. 28 para. 11; see also Senju et
`
`al. v. Lupin et al., C.A. 14:-cv-00667 (D.N.J.) ECF 34) (“Discovery
`
`Confidentiality Order”); and
`
`(3) Petitioners’ Replies, the Declaration of Ivan Hoffmann, and the
`
`Declaration of Dr. Paul Laskar filed concurrently herewith in IPR2015-
`
`00902 and IPR2015-00902, which contain or refer to information contained
`
`in the aforementioned transcripts designated confidential by the Patent
`
`Owner, documents designated as Protective Order Material Confidential
`
`
`
`1
`
`
`
`
`
`under the Proposed Stipulated Protective Order by the Patent Owner,
`
`documents designated as Confidential under the Discovery Confidentiality
`
`Order by the Patent Owner, or testimony designated as Protective Order
`
`Material - Fed. R. Evid. 615 under the Proposed Stipulated Protective Order
`
`by the Patent Owner.
`
`The record of an inter partes review proceeding, including documents and
`
`things, is made available to the public, except as otherwise ordered. 37 C.F.R. §
`
`42.14. Despite the default rule of public availability, the Board will seal
`
`confidential information for “good cause,” because it is necessary to “strike a
`
`balance between
`
`the public’s
`
`interest
`
`in maintaining a complete and
`
`understandable file history and the parties’ interest in protecting truly sensitive
`
`information.” 37 C.F.R. § 42.54(a); 77 Fed. Reg. 48756, 48760 (Aug. 14, 2012).
`
`It is Petitioner’s understanding that information in the following documents
`
`has been designated as confidential to Patent Owner, pursuant to the Proposed
`
`Stipulated Protective Order:
`
`•
`
`•
`
`
`
`Portions of EX1083 (Myers Transcript), 141:9-203:10.
`
`Portions of EX1082 (Paulson Transcript), 71:13-74:11, 105:13-106:13,
`
`107:4-11, 108:19-109:4, 109:11-16, 113:1-7, 113:16-116:22, 118:7-123:14,
`
`124:11-22, 125:5-6, 125:12-20, 126:2-8, 126:12-22, 127:6-128:3, 128:17-19,
`
`131:5-132:6, 132:9, 132:12-133:21, 134:8-135:1, 137-142:12, 143:21-144:1,
`
`2
`
`
`
`
`
`•
`
`•
`
`•
`
`•
`
`•
`
`•
`
`•
`
`
`
`144:7-22, 145:14-146:7, 146:13-15, 146:19-147:9, 147:15-22, 148:12-18,
`
`149:3-7, 149:12-14, 149:17-151:19, 152:15-153:4, 156:10-157:12, 159:7-
`
`160:9, 170:19-172:7, 180:9-12, 181:13-19, 182:6-183:9, 183:19-184:19,
`
`187:13-188:15, 191:16-312:10.
`
`Portions of EX1081 (Trattler Transcript), 111:10-12.
`
`Portions of EX1079 (Williams Transcript), 121:5-18, 122:7-20, 123:1-
`
`125:16, 126:4-127:2.
`
`Portions of EX1049 (Jarosz Transcript), 8:17-18, 9:5-8, 97:5-98:16, 107:7-
`
`111:11.
`
`Portions of EX1150 (Hofmann Declaration)
`
`Portions of EX1104 (Laskar Declaration)
`
`Portions of Petitioner’s Reply to Patent Owner’s Response
`
`The entirety of EX1067, EX1117, EX1134, EX1140, and EX1152
`
`3
`
`
`
`
`
`Patent Owner has requested that Petitioner file these documents under seal
`
`and file an appropriate motion to seal under the Proposed Stipulated Protective
`
`Order. (See Appendix A and Appendix B attached hereto). Petitioner has no
`
`independent basis for the aforementioned documents to be sealed and thus makes
`
`no assertion as to whether or not they contain confidential information. Patent
`
`RESPECTFULLY SUBMITTED,
`
`ALSTON & BIRD LLP
`
`
`
`
`
`
`
`/Jitendra Malik/
`
`Jitendra Malik (Reg. No. 55823)
`Reg. No. 55823
`Alston & Bird LLP
`4721 Emperor Blvd., Suite 400
`Durham, NC 27703-8580
`jitty.malik@alston.com
`
`Lead Counsel for Petitioner
`
`
`4
`
`owner does not oppose this motion.
`
`
`
`Date: March 18, 2015
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`CERTIFICATION OF SERVICE
`
`Pursuant to 37 C.F.R. §§ 42.6(e), 42.8(b)(4) and 42.105, the undersigned
`
`certifies that on the 18th day of March, 2016, a complete copy of the foregoing
`
`Petitioner’s Motion to Seal was served on counsel of record for the Patent Owner:
`
`Senju Pharmaceutical Co., Ltd., et al.
`
`Bryan C. Diner
`bryan.diner@finnegan.com
`
`Justin J. Hasford
`justin.hasford@finnegan.com
`
`Joshua L. Goldberg
`Joshua.goldberg@finnegan.com
`
`
`
`
`
`Respectfully submitted,
`
`Alston & Bird LLP
`
`By: /Jitendra Malik/
`
`Jitendra Malik, Ph.D.
`Reg. No. 55823
`Alston & Bird LLP
`4721 Emperor Blvd., Suite 400
`Durham, NC 27703-8580
`jitty.malik@alston.com
`
`Bryan Skelton, Ph.D.
`Reg. No. 50893
`Alston & Bird LLP
`4721 Emperor Blvd., Suite 400
`Durham, NC 27703-8580
`bryan.skelton@alston.com
`
`1
`
`
`
`
`Lance Soderstrom
`Reg. No. 65405
`Alston & Bird LLP
`90 Park Avenue
`15th Floor
`New York, NY 10016-1387
`lance.soderstrom@alston.com
`
`Hidetada James Abe
`Reg. No. 61,182
`Alston & Bird LLP
`333 South Hope Street
`16th Floor
`Los Angeles, CA 90071
`james.abe@alston.com
`
`Joseph M. Janusz
`Reg. No. 70396
`ALSTON & BIRD LLP
`101 S. Tryon Street, Suite 4000
`Charlotte, NC 28205
`Telephone: 704-444-1000
`Fax: 704-444-1111
`joe.janusz@alston.com
`
`Attorneys for Petitioners InnoPharma
`Licensing, Inc., InnoPharma Licensing
`LLC, InnoPharma Inc., InnoPharma
`LLC, Mylan Pharmaceuticals Inc., and
`Mylan Inc.
`
`
`
`Deborah H. Yellin (Reg. No. 45,904)
`Crowell & Moring LLP
`Intellectual Property Group
`1001 Pennsylvania Avenue, N.W.
`Washington, DC 20004-2595
`Telephone No.: (202) 624-2947
`Facsimile No.: (202) 628-5116
`
`2
`
`
`
`
`
`
`
`
`
`DYellin@Crowell.com
`
`Jonathan Lindsay (Reg. No. 45,810)
`Crowell & Moring LLP
`Intellectual Property Group
`3 Park Plaza, 20th Floor
`Irvine, CA 92614-8505
`Telephone No.: (949) 798-1325
`Facsimile No.: (949) 263-8414
`JLindsay@Crowell.com
`
`Attorneys for Petitioners Lupin Ltd. and
`Lupin Pharmaceuticals, Inc.
`
`
`3
`
`
`
`Appendix A
`Appendix A
`
`
`
`IPR2015-00902
`IPR2015-00902
`IPR2015-00903
`IPR2015-00903
`
`
`
`
`
`
`
`Elizabeth D. Ferrill
`Attorney at Law
`Finnegan, Henderson, Farabow, Garrett & Dunner, LLP
`901 New York Avenue, NW, Washington, DC 20001-4413
`202.408.4445 | fax: 202.408.4400 | elizabeth.ferrill@finnegan.com | www.finnegan.com
`
`
`
`
`
`
`
`This e-mail message is intended only for individual(s) to whom it is addressed and may contain information that is privileged, confidential, proprietary, or otherwise
`exempt from disclosure under applicable law. If you believe you have received this message in error, please advise the sender by return e-mail and delete it from
`your mailbox. Thank you.
`
`
`
`Appendix B
`Appendix B
`
`
`
`IPR2015-00902
`IPR2015-00902
`IPR2015-00903
`IPR2015-00903
`
`
`
`
`
`
`
`Elizabeth D. Ferrill
`Attorney at Law
`Finnegan, Henderson, Farabow, Garrett & Dunner, LLP
`901 New York Avenue, NW, Washington, DC 20001-4413
`202.408.4445 | fax: 202.408.4400 | elizabeth.ferrill@finnegan.com | www.finnegan.com
`
`
`
`H. James Abe
`Alston & Bird LLP
`333 S. Hope Street, 16th Floor, Los Angeles, California 90071
`direct: 213-576-1060 | fax: 213-576-1100 | cell: 714-209-3505
`james.abe@alston.com | www.alston.com
`
`H. James Abe
`
`
`
`Alston & Bird LLP
`333 S. Hope Street, 16th Floor, Los Angeles, California 90071
`direct: 213-576-1060 | fax: 213-576-1100 | cell: 714-209-3505
`james.abe@alston.com | www.alston.com
`
`
`
`
`
`This e-mail message is intended only for individual(s) to whom it is addressed and may contain information that is privileged, confidential, proprietary, or otherwise
`exempt from disclosure under applicable law. If you believe you have received this message in error, please advise the sender by return e-mail and delete it from
`your mailbox. Thank you.